UNCOVERING THE MECHANISMS OF OSTEOSARCOMA METASTASIS SUPPRESSION BY MTBP
UNCOVERING THE MECHANISMS OF OSTEOSARCOMA METASTASIS SUPPRESSION BY MTBP
批准号:
8360720
负责人:
Tomoo Iwakuma
金额:
$22.35万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-17 至 2012-07-31
关键词:
AffectAllelesAttenuatedBAX geneBindingBinding ProteinsCell CycleDevelopmentFundingG1 ArrestGADD45Genetic ProgrammingGenetic TranscriptionGoalsGrantKnock-outKnockout MiceMalignant NeoplasmsMentorsMetastasis SuppressionMetastatic OsteosarcomaMusMutateNational Center for Research ResourcesNeoplasm MetastasisOsteoblastsPathway interactionsPatientsPlayPrincipal InvestigatorProteinsProtocols documentationResearchResearch InfrastructureResourcesRoleSourceStressTP53 geneTumor Suppressor ProteinsUnited States National Institutes of HealthWorkbasecancer geneticscostdesignin vivoinhibitor/antagonistmutantnovelosteosarcomaoutcome forecasttherapeutic developmenttumoryeast two hybrid system
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
Our long-term goal is to elucidate the impact of the Mdm2-p53 pathway in vivo on tumor development as a necessary prerequisite to the development of therapeutic protocols for attenuating cancer. p53 functions as a tumor suppressor and exerts this function by activating numerous downstream targets such as p21, BAX, PUMA, GADD45 as a transcription factor1. Mdm2 is a major inhibitor of p53 through physical binding and induction of p53 degradation2. The p53 gene is mutated in more than 50% of tumors, and Mdm2 is highly expressed in a variety of tumors, stressing the importance of the Mdm2-p53 pathway in tumor development 3-6. It should be noted that a significant number of tumors have wild-type p53 with Mdm2 over-expression. Interestingly, some patients with tumors in which p53 gene is mutated and Mdm2 is over-expressed are known to have a poorer prognosis, compared to patients with mutant p53 alone in tumors7, 8. These results suggest that Mdm2 also has p53-independent roles in tumor development. Recently, Mdm2 is found to inhibitory interact with other tumor suppressors such as Rb, PML, and p73, which may contribute to p53-independent roles of Mdm2 in tumor development9-15. One can assume that any proteins that affect Mdm2 function may have an impact on tumor development.
Mdm2 Binding Protein (MTBP) was isolated by Boyd MT et al.16 using the yeast two hybrid system with Mdm2 as bait. Over-expression of MTBP causes G1 arrest of cell cycle, but the effect is nullified by simultaneous over-expression of Mdm2. Our working hypothesis is that MTBP plays a critical role in tumor development and metastasis. This hypothesis is based on our preliminary results using a conventional mtbp knockout mouse in which we observed that (1) 30% of mtbp heterozygous mice spontaneously developed tumors within 22 months, and (2) doubly heterozygous knockout mice for mtbp and p53 developed metastatic osteosarcomas. Based on these observations, the focus of this proposal is on the roles of MTBP in osteosarcoma metastasis and the functional characterization of this protein. The specific aims are designed to provide a comprehensive assessment of novel functions of MTBP, especially in osteosarcoma metastasis.
Aim 1. To characterize osteosarcomas induced by loss of mtbp.
Aim 2. To generate and characterize mice with conditional mtbp and/or p53 knockout alleles, specifically in osteoblasts.
Aim 3. To isolate MTBP interacting proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The 10th International MDM2 Workshop
-
批准号:10814471
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2023
-
负责人:Tomoo Iwakuma
-
依托单位:
Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis
-
批准号:10320158
-
项目类别:
-
资助金额:$38.4万
-
财政年份:2021
-
负责人:Tomoo Iwakuma
-
依托单位:
Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis
-
批准号:10339474
-
项目类别:
-
资助金额:$34.28万
-
财政年份:2021
-
负责人:Tomoo Iwakuma
-
依托单位:
Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis
-
批准号:9523990
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2018
-
负责人:Tomoo Iwakuma
-
依托单位:
The role of MDM2-MTBP axis in cancer metastasis
-
批准号:8694358
-
项目类别:
-
资助金额:$31.33万
-
财政年份:2014
-
负责人:Tomoo Iwakuma
-
依托单位:
The role of MDM2-MTBP axis in cancer metastasis
-
批准号:8842602
-
项目类别:
-
资助金额:$31.33万
-
财政年份:2014
-
负责人:Tomoo Iwakuma
-
依托单位:
DISSECTING ROLES OF MTBP IN OSTEOSARCOMA METASTASIS
-
批准号:7720778
-
项目类别:
-
资助金额:$34.63万
-
财政年份:2008
-
负责人:Tomoo Iwakuma
-
依托单位:
DISSECTING ROLES OF MTBP IN OSTEOSARCOMA METASTASIS
-
批准号:7610681
-
项目类别:
-
资助金额:$33.52万
-
财政年份:2007
-
负责人:Tomoo Iwakuma
-
依托单位:
UNCOVERING THE MECHANISMS OF OSTEOSARCOMA METASTASIS SUPPRESSION BY MTBP
-
批准号:8168370
-
项目类别:
-
资助金额:$17.73万
-
财政年份:2004
-
负责人:Tomoo Iwakuma
-
依托单位:
DISSECTING ROLES OF MTBP IN OSTEOSARCOMA METASTASIS
-
批准号:7960535
-
项目类别:
-
资助金额:$22.1万
-
财政年份:2004
-
负责人:Tomoo Iwakuma
-
依托单位:
海外基金